NSE - Free Realtime Quote INR

Aurobindo Pharma Limited (AUROPHARMA.NS)

1,146.80
-10.80
(-0.93%)
As of 9:16:29 AM GMT+5:30. Market Open.

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.
NameTitlePayExercisedYear Born
Mr. Kambam Nithyananda Reddy Vice Chairman & MD 45.05M -- 1958
Mr. Mettu Madan Mohan Reddy Whole-Time Director 60.15M -- 1960
Dr. Makkapati Satakarni B.E., M.B.A., Ph.D. President of Biologics, CEO of Biologics, Vaccines and Peptid & Director 300k -- 1981
Mr. Santhanam Subramanian Chief Financial Officer 21.06M -- 1961
Dr. S. Vijaya Kumar President of Technical -- -- 1966
Mr. B. Adi Reddy Compliance Officer & Company Secretary 4.76M -- --
Mr. G. P. Prasad Senior Vice President of Global Finance & Operations -- -- --
Dr. Sudhir Bimal Singhi Head of Global Finance Operations -- -- 1969
Dr. A. Rama Mohana Rao Chief Quality Officer -Corporate QA -- -- 1962
Dr. V. K. Handa President of Chemical Research -- -- 1952

Aurobindo Pharma Limited

Galaxy, Plot No. 1
22nd-24th Floor Plot No.1, Survey No.83/1 Hyderabad Knowledge City,Raidurg Panmakt
Hyderabad, 500032
India
91 40 6672 5000 https://www.aurobindo.com
Sector: 
Healthcare
Full Time Employees: 
26,015

Description

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Corporate Governance

Aurobindo Pharma Limited’s ISS Governance QualityScore as of May 1, 2025 is 2. The pillar scores are Audit: 9; Board: 4; Shareholder Rights: 1; Compensation: 1.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 23, 2025 at 10:59 AM UTC - May 27, 2025 at 12:00 PM UTC

Aurobindo Pharma Limited Earnings Date

Recent Events

February 20, 2024 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers